BRPI0906099A2 - "método de tratamento do câncer em um indivíduo" - Google Patents

"método de tratamento do câncer em um indivíduo"

Info

Publication number: BRPI0906099A2
Authority: BR; Brazil
Prior art keywords: individual; treatment method; cancer treatment; cancer; treatment
Prior art date: 2008-03-06

Application number

BRPI0906099-5A

Other languages

English (en)

Inventor

Ellen Filvaroff

Robert L Yauch

Mark Merchant

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-06

Filing date

2009-03-06

Publication date

2015-07-21

2009-03-06 Application filed by Genentech Inc filed Critical Genentech Inc

2015-07-21 Publication of BRPI0906099A2 publication Critical patent/BRPI0906099A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Mycology (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Oncology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

BRPI0906099-5A 2008-03-06 2009-03-06 "método de tratamento do câncer em um indivíduo" BRPI0906099A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US3444608P	2008-03-06	2008-03-06
US4443808P	2008-04-11	2008-04-11
PCT/US2009/036314 WO2009111691A2 (en)	2008-03-06	2009-03-06	Combination therapy with c-met and egfr antagonists

Publications (1)

Publication Number	Publication Date
BRPI0906099A2 true BRPI0906099A2 (pt)	2015-07-21

Family

ID=40688402

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0906099-5A BRPI0906099A2 (pt)	2008-03-06	2009-03-06	"método de tratamento do câncer em um indivíduo"

Country Status (20)

Country	Link
US (3)	US20090226443A1 (pt)
EP (1)	EP2257293A2 (pt)
JP (1)	JP2011513427A (pt)
KR (2)	KR20100135780A (pt)
CN (1)	CN102014913A (pt)
AR (1)	AR070861A1 (pt)
AU (1)	AU2009221808A1 (pt)
BR (1)	BRPI0906099A2 (pt)
CA (1)	CA2716851A1 (pt)
CL (1)	CL2009000542A1 (pt)
CR (1)	CR11717A (pt)
EC (1)	ECSP10010527A (pt)
IL (1)	IL207777A0 (pt)
MA (1)	MA32177B1 (pt)
MX (1)	MX2010009669A (pt)
RU (1)	RU2601892C2 (pt)
SG (1)	SG188802A1 (pt)
TW (1)	TW200940064A (pt)
WO (1)	WO2009111691A2 (pt)
ZA (1)	ZA201006028B (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2008146868A (ru)	2006-05-18	2010-06-27	Кэрис МПИ, Инк.445 Норт Фифс Стрит, 3-ий Флор, Феникс, Аризона 85004, США (US)	Система и способ определения персонализированого медицинского вмешательства при болезненном состоянии
US8768629B2 (en)	2009-02-11	2014-07-01	Caris Mpi, Inc.	Molecular profiling of tumors
AR070862A1 (es) *	2008-03-06	2010-05-12	Genentech Inc	Terapia de combinacion con antagonistas de c- met y her
EP2349328A1 (en) *	2008-10-01	2011-08-03	Ludwig Institute For Cancer Research	Methods for the treatment of cancer
AU2009299791B2 (en) *	2008-10-01	2016-02-25	Amgen Research (Munich) Gmbh	Cross-species-specific PSCAxCD3, CD19xCD3, C-METxCD3, EndosialinxCD3, EpCAMxC D3, IGF-1RxCD3 or FAPalpha xCD3 bispecific single chain antibody
US20110262436A1 (en) *	2008-10-17	2011-10-27	Genentech, Inc.	Treatment method
JP5612663B2 (ja)	2009-04-07	2014-10-22	ロシュグリクアートアクチェンゲゼルシャフト	二重特異性抗ＥｒｂＢ−１／抗ｃ−Ｍｅｔ抗体
CA2757531A1 (en)	2009-04-07	2010-10-14	Roche Glycart Ag	Bispecific anti-erbb-3/anti-c-met antibodies
WO2011057120A1 (en)	2009-11-05	2011-05-12	Genentech, Inc.	Methods and composition for secretion of heterologous polypeptides
TWI518325B (zh)	2010-02-04	2016-01-21	自治醫科大學	對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
CA3254586A1 (en) *	2010-03-10	2025-11-29	Genmab A/S	Monoclonal anti bodi es against c-met
WO2011125458A1 (ja) *	2010-04-02	2011-10-13	富士レビオ株式会社	抗癌剤の効果の診断用マーカー
WO2012003338A1 (en) *	2010-07-01	2012-01-05	Takeda Pharmaceutical Company Limited	COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
RU2013114360A (ru)	2010-08-31	2014-10-10	Дженентек, Инк.	Биомаркеры и способы лечения
WO2012064967A2 (en) *	2010-11-10	2012-05-18	Cedars-Sinai Medical Center	Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases
BR112013022307A2 (pt)	2011-03-04	2020-09-24	Glaxosmithkline Intellectual Property (No. 2) Limited	aminoquinolinas como inibidores de quinase
CN102796109B (zh) *	2011-05-23	2015-10-07	复旦大学	4-氨基喹唑啉化合物及其制备方法和用途
AU2012267888A1 (en) *	2011-06-07	2014-01-30	Caris Mpi, Inc.	Molecular profiling for cancer
KR20140045440A (ko)	2011-06-30	2014-04-16	제넨테크, 인크.	항-c-met 항체 제제
TWI547494B (zh) *	2011-08-18	2016-09-01	葛蘭素史克智慧財產發展有限公司	作為激酶抑制劑之胺基喹唑啉類
AU2012304362A1 (en) *	2011-09-09	2014-03-06	Amgen Inc.	Use of c-Met protein for predicting the efficacy of anti-hepatocyte growth factor ("HGF") antibodies in esophageal and gastric cancer patients
TWI594986B (zh) *	2011-12-28	2017-08-11	Taiho Pharmaceutical Co Ltd	Antineoplastic agent effect enhancer
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
AR092529A1 (es)	2012-09-13	2015-04-22	Glaxosmithkline Llc	Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
KR20250054125A (ko)	2012-11-21	2025-04-22	얀센 바이오테크 인코포레이티드	이중특이성 EGFR/c-Met 항체
US20170275367A1 (en)	2012-11-21	2017-09-28	Janssen Biotech, Inc.	Bispecific EGFR/C-Met Antibodies
US9695228B2 (en)	2012-11-21	2017-07-04	Janssen Biotech, Inc.	EGFR and c-Met fibronectin type III domain binding molecules
TWI630203B (zh)	2013-02-21	2018-07-21	葛蘭素史克智慧財產發展有限公司	做為激酶抑制劑的喹唑啉類
CN103113365B (zh) *	2013-02-22	2015-06-17	苏州大学	罗丹宁喹唑啉胺复合物及其制备方法和用途
KR102029137B1 (ko)	2013-03-27	2019-10-08	삼성전자주식회사	EGFR 길항제 및 항 c-Met 항체를 포함하는 병용 투여용 약학 조성물
KR102049991B1 (ko)	2013-03-28	2019-12-02	삼성전자주식회사	항 c-Met/항 Her2 이중 특이 항체
US20160058751A1 (en) *	2013-03-28	2016-03-03	Cellworks Group, Inc.	Composition and method for treating cancer
KR20140119396A (ko) *	2013-03-29	2014-10-10	삼성전자주식회사	단백질 약물의 액상 제형
KR102074421B1 (ko)	2013-03-29	2020-02-10	삼성전자주식회사	항 c-Met/항 EGFR 이중 특이 항체
KR102060540B1 (ko)	2013-04-03	2019-12-31	삼성전자주식회사	항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
US9381246B2 (en) *	2013-09-09	2016-07-05	Triact Therapeutics, Inc.	Cancer therapy
KR102478402B1 (ko)	2013-10-14	2022-12-15	얀센 바이오테크 인코포레이티드	시스테인 조작된 피브로넥틴 iii형 도메인 결합 분자
US9717715B2 (en) *	2013-11-15	2017-08-01	Samsung Electronics Co., Ltd.	Method of combination therapy using an anti-C-Met antibody
TW201609805A (zh)	2013-12-23	2016-03-16	美國禮來大藥廠	結合ｅｇｆｒ及ｍｅｔ之多功能抗體
KR102194142B1 (ko) *	2014-01-20	2020-12-23	삼성전자주식회사	항 c-Met/항 EGFR 이중 특이 항체 및 c-Src 저해제를 포함하는 병용 투여용 약학 조성물
KR102291465B1 (ko) *	2014-01-24	2021-08-18	삼성전자주식회사	c-Met 저해제의 효능 예측을 위한 바이오마커 TFF1
AU2015229035B2 (en)	2014-03-14	2021-08-05	Genentech, Inc.	Methods and compositions for secretion of heterologous polypeptides
WO2015148531A1 (en) *	2014-03-24	2015-10-01	Genentech, Inc.	Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
KR102223502B1 (ko)	2014-05-09	2021-03-05	삼성전자주식회사	항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
KR102309881B1 (ko)	2014-11-21	2021-10-06	삼성전자주식회사	c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
WO2017136820A2 (en) *	2016-02-06	2017-08-10	Epimab Biotherapeutics, Inc.	Fabs-in-tandem immunoglobulin and uses thereof
WO2017201156A1 (en) *	2016-05-18	2017-11-23	Duke University	Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab
SG11201811062XA (en)	2016-06-21	2019-01-30	Janssen Biotech Inc	Cysteine engineered fibronectin type iii domain binding molecules
TWI782930B (zh)	2016-11-16	2022-11-11	美商再生元醫藥公司	抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
BR112019012154A2 (pt)	2016-12-14	2019-11-12	Janssen Biotech, Inc.	domínios do tipo iii da fibronectina de ligação a cd8a
EP3554561B1 (en)	2016-12-14	2023-06-28	Janssen Biotech, Inc.	Cd137 binding fibronectin type iii domains
EP3554535A4 (en)	2016-12-14	2020-10-21	Janssen Biotech, Inc.	PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
EP3554495B1 (en)	2016-12-19	2025-06-04	Merck Patent GmbH	Combination of a protein kinase inhibitor and an additional chemotherapeutic agent
DK3583943T3 (da)	2017-02-15	2024-10-14	Taiho Pharmaceutical Co Ltd	Farmaceutisk sammensætning
US12280045B2 (en)	2017-09-08	2025-04-22	Taiho Pharmaceutical Co., Ltd.	Antitumor agent and antitumor effect potentiator
CN108324990A (zh) *	2018-02-11	2018-07-27	温州优墨生物科技有限公司	一种骨材料脱细胞的方法及制备脱细胞骨粉的方法
US12060427B2 (en) *	2018-03-28	2024-08-13	Mitsubishi Tanabe Pharma Corporat	Drug conjugates of cMET monoclonal binding agents, and uses thereof
CA3097916A1 (en)	2018-05-03	2019-11-07	Shanghai Epimab Biotherapeutics Co., Ltd.	High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom
SG11202112412QA (en) *	2019-05-14	2021-12-30	Janssen Biotech Inc	Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
US11879013B2 (en)	2019-05-14	2024-01-23	Janssen Biotech, Inc.	Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
JP7750828B2 (ja)	2019-09-16	2025-10-07	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質
US12491255B2 (en)	2019-10-14	2025-12-09	Aro Biotherapeutics Company	EPCAM binding fibronectin type III domains
US11781138B2 (en)	2019-10-14	2023-10-10	Aro Biotherapeutics Company	FN3 domain-siRNA conjugates and uses thereof
EP4045061A4 (en)	2019-10-14	2024-04-17	ARO Biotherapeutics Company	CD71-BINDING FIBRONECTIN TYPE III DOMAINS
CN117098537A (zh) *	2020-12-11	2023-11-21	医睿世康药业研发公司	用于癌症治疗的联合疗法
WO2022125962A1 (en) *	2020-12-11	2022-06-16	Erasca, Inc.	Combination therapies for the treatment of cancer
CA3215367A1 (en)	2021-04-14	2022-10-20	Swapnil Kulkarni	Fn3 domain-sirna conjugates and uses thereof
EP4323409A4 (en)	2021-04-14	2025-04-16	ARO Biotherapeutics Company	CD71-BINDING FIBRONECTIN TYPE III DOMAINS
WO2025235874A1 (en) *	2024-05-10	2025-11-13	Schrödinger, Inc.	Heterocyclics as egfr inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU4128089A (en) *	1988-09-15	1990-03-22	Rorer International (Overseas) Inc.	Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6524832B1 (en) *	1994-02-04	2003-02-25	Arch Development Corporation	DNA damaging agents in combination with tyrosine kinase inhibitors
US5731168A (en) *	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5686292A (en) *	1995-06-02	1997-11-11	Genentech, Inc.	Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5747498A (en) *	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
US7087613B2 (en) *	1999-11-11	2006-08-08	Osi Pharmaceuticals, Inc.	Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) *	1999-11-11	2006-02-15	Осі Фармасьютікалз, Інк.	Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
DK2857516T3 (en) *	2000-04-11	2017-08-07	Genentech Inc	Multivalent antibodies and uses thereof
US7332580B2 (en) *	2002-04-05	2008-02-19	The Regents Of The University Of California	Bispecific single chain Fv antibody molecules and methods of use thereof
US7220410B2 (en) *	2003-04-18	2007-05-22	Galaxy Biotech, Llc	Monoclonal antibodies to hepatocyte growth factor
WO2005001486A1 (en) *	2003-06-06	2005-01-06	Genentech, Inc.	Modulating the interaction between hgf beta chain and c-met
HN2004000285A (es) *	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
CN1922208A (zh) *	2003-12-11	2007-02-28	健泰科生物技术公司	用于抑制c－met二聚化及活化的方法和组合物
BRPI0510716A (pt) *	2004-05-05	2007-11-20	Merrimack Pharmaceuticals Inc	uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
CA2569520C (en) *	2004-06-04	2023-03-14	Genentech, Inc.	Kras mutations for identifying colorectal tumors responsive to cetuximab or panitumumab
ES2344793T3 (es) *	2004-08-05	2010-09-07	Genentech, Inc.	Antagonistas anti-cmet humanizados.
JP2008531557A (ja) *	2005-02-23	2008-08-14	メリマックファーマシューティカルズインコーポレーティッド	生物活性を調節するための二重特異性結合剤
ATE477495T1 (de) *	2005-03-16	2010-08-15	Osi Pharm Inc	Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
US8383357B2 (en) *	2005-03-16	2013-02-26	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US20060216288A1 (en) *	2005-03-22	2006-09-28	Amgen Inc	Combinations for the treatment of cancer
JP2008535821A (ja) *	2005-03-25	2008-09-04	ジェネンテック・インコーポレーテッド	過剰に安定化したｃ−ｍｅｔを調節するための方法及び組成物
JP2009526761A (ja) *	2006-01-30	2009-07-23	アレイバイオファーマ、インコーポレイテッド	ヘテロ二環式チオフェン化合物および使用の方法
EP2001880A2 (en) *	2006-03-07	2008-12-17	Array Biopharma, Inc.	Heterobicyclic pyrazole compounds and methods of use
WO2007126799A2 (en) *	2006-03-30	2007-11-08	Novartis Ag	Compositions and methods of use for antibodies of c-met
AR059922A1 (es) *	2006-04-01	2008-05-07	Galaxy Biotech Llc	Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
JP2009539878A (ja) *	2006-06-08	2009-11-19	アレイバイオファーマ、インコーポレイテッド	キノリン化合物および使用方法
WO2008027236A2 (en) *	2006-08-30	2008-03-06	Genentech, Inc.	Multispecific antibodies
AU2007353412A1 (en) *	2006-11-21	2008-11-20	Fox Chase Cancer Center	Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
EP2851091B1 (en) *	2007-04-13	2017-12-27	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer resistant to ERBB therapeutics
JP2010538094A (ja) *	2007-09-06	2010-12-09	アレイバイオファーマ、インコーポレイテッド	チロシンキナーゼ阻害剤としてのピラゾロピリジン類
AR073231A1 (es) *	2008-08-29	2010-10-20	Genentech Inc	Metodos diagnosticos y tratamientos para los tumores independientes del vegf (factor de crecimiento endotelial vascular)
US20110262436A1 (en) *	2008-10-17	2011-10-27	Genentech, Inc.	Treatment method
ES2572728T3 (es) *	2009-03-20	2016-06-02	F. Hoffmann-La Roche Ag	Anticuerpos anti-HER biespecíficos
JP5612663B2 (ja) *	2009-04-07	2014-10-22	ロシュグリクアートアクチェンゲゼルシャフト	二重特異性抗ＥｒｂＢ−１／抗ｃ−Ｍｅｔ抗体
WO2011057120A1 (en) *	2009-11-05	2011-05-12	Genentech, Inc.	Methods and composition for secretion of heterologous polypeptides
AU2011252804A1 (en) *	2010-05-14	2012-10-04	Genentech, Inc.	Treatment methods
US8580764B2 (en) *	2010-07-01	2013-11-12	Arqule, Inc.	Combinational compositions and methods for treatment of cancer
RU2013114360A (ru) *	2010-08-31	2014-10-10	Дженентек, Инк.	Биомаркеры и способы лечения

2009
- 2009-03-06 KR KR1020107022230A patent/KR20100135780A/ko not_active Ceased
- 2009-03-06 MX MX2010009669A patent/MX2010009669A/es not_active Application Discontinuation
- 2009-03-06 BR BRPI0906099-5A patent/BRPI0906099A2/pt not_active IP Right Cessation
- 2009-03-06 AR ARP090100815A patent/AR070861A1/es unknown
- 2009-03-06 KR KR1020167020709A patent/KR20160095186A/ko not_active Ceased
- 2009-03-06 JP JP2010549904A patent/JP2011513427A/ja active Pending
- 2009-03-06 AU AU2009221808A patent/AU2009221808A1/en not_active Abandoned
- 2009-03-06 CA CA2716851A patent/CA2716851A1/en not_active Abandoned
- 2009-03-06 CN CN2009801164913A patent/CN102014913A/zh active Pending
- 2009-03-06 RU RU2010140795/15A patent/RU2601892C2/ru not_active IP Right Cessation
- 2009-03-06 WO PCT/US2009/036314 patent/WO2009111691A2/en not_active Ceased
- 2009-03-06 CL CL2009000542A patent/CL2009000542A1/es unknown
- 2009-03-06 EP EP09716498A patent/EP2257293A2/en not_active Withdrawn
- 2009-03-06 TW TW098107445A patent/TW200940064A/zh unknown
- 2009-03-06 SG SG2013013255A patent/SG188802A1/en unknown
- 2009-03-06 US US12/399,866 patent/US20090226443A1/en not_active Abandoned
2010
- 2010-08-24 ZA ZA2010/06028A patent/ZA201006028B/en unknown
- 2010-08-24 IL IL207777A patent/IL207777A0/en unknown
- 2010-09-30 MA MA33214A patent/MA32177B1/fr unknown
- 2010-10-05 CR CR11717A patent/CR11717A/es not_active Application Discontinuation
- 2010-10-06 EC EC2010010527A patent/ECSP10010527A/es unknown
2014
- 2014-03-05 US US14/198,359 patent/US20150056207A1/en not_active Abandoned
2015
- 2015-12-17 US US14/973,459 patent/US20160303127A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2716851A1 (en)	2009-09-11
RU2010140795A (ru)	2012-04-20
US20090226443A1 (en)	2009-09-10
AU2009221808A1 (en)	2009-09-11
ECSP10010527A (es)	2010-11-30
IL207777A0 (en)	2010-12-30
CN102014913A (zh)	2011-04-13
WO2009111691A2 (en)	2009-09-11
EP2257293A2 (en)	2010-12-08
KR20100135780A (ko)	2010-12-27
KR20160095186A (ko)	2016-08-10
SG188802A1 (en)	2013-04-30
CR11717A (es)	2010-11-26
MA32177B1 (fr)	2011-03-01
CL2009000542A1 (es)	2010-11-05
RU2601892C2 (ru)	2016-11-10
MX2010009669A (es)	2010-09-22
JP2011513427A (ja)	2011-04-28
US20160303127A1 (en)	2016-10-20
TW200940064A (en)	2009-10-01
AR070861A1 (es)	2010-05-12
ZA201006028B (en)	2011-11-30
WO2009111691A3 (en)	2009-11-12
US20150056207A1 (en)	2015-02-26

Publication	Publication Date	Title
BRPI0906099A2 (pt)	2015-07-21	"método de tratamento do câncer em um indivíduo"
BRPI0810206A2 (pt)	2014-10-21	Método de tratar câncer
GB2463797B (en)	2010-08-25	Skin treating device
BRPI0910854A2 (pt)	2015-10-06	métodos de tratamento
PL2282675T3 (pl)	2017-02-28	System do zabiegu kosmetycznego i obrazowania
BRPI0916125A2 (pt)	2015-11-03	"dispositivo de tratamento"
BRPI0812585A2 (pt)	2015-02-18	Aparelho de tratamento de redução e método de tratamento de redução
BRPI0910259A2 (pt)	2015-12-01	métodos de tratamento de inflamação
BRPI1007477A2 (pt)	2016-02-16	método, e, composição de tratamento de poço
IL212348A0 (en)	2011-06-30	Treatment method
IT1391555B1 (it)	2012-01-11	Apparato trattamento extracorporeo sangue
BRPI0919150A2 (pt)	2015-12-08	aplicadores de fluxo de ar e métodos de tratamento relacionados
BRPI0914082A2 (pt)	2015-10-27	"método de espectroscopia e aparelho de espectroscopia"
BRPI0919748A2 (pt)	2015-12-08	dipositivo de tratamento
PT2340042E (pt)	2014-11-27	Métodos e composições para o tratamento de cancro
BRPI0908635A2 (pt)	2015-10-13	composto, composição farmacêutica e método de tratamento de câncer
BRPI0909164A2 (pt)	2016-06-21	método e composições para o tratamento de câncer
BRPI0918103A2 (pt)	2016-07-05	"método para o tratamento da dor em um indivíduo"
IL238394A0 (en)	2015-06-30	Cancer treatment method
BRPI0812932A2 (pt)	2014-12-09	Composições e métodos de tratar câncer
PL2187967T3 (pl)	2013-09-30	Sposoby i kompozycje do leczenia raka
PL2131841T3 (pl)	2013-03-29	Sposoby leczenia bólu ostrego
BRPI0822129A2 (pt)	2015-06-23	Inibidores de aldh-2c no tratamento de vício.
GB0718684D0 (en)	2007-10-31	Treatment method
HRP20160577T1 (hr)	2016-07-29	Liječenje osteoartritisa

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-11-13	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-01-02	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 10A ANUIDADE.
2019-04-24	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2504 DE 02-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.